ANXA5 and breast cancer: The WHC treatment showed dose- and time-dependent increases in the apoptotic (annexin V) population of breast cancer (SKBR3 and MCF7) cells (Figure 3B,D), which was higher than that of normal breast (M10) cells (Figure 3B).